CLAIMS

[Claim 1]
Use of hsa-miR-140-5p and hsa-miR-126-3p for manufacturing a prophylactic or therapeutic agent for a disease or condition associated with angiogenesis.

[Claim 2]
Use of hsa-miR-140-5p for manufacturing an agent for preventing or treating a disease or condition associated with angiogenesis through combined use with hsa-miR-126-3p.

[Claim 3]
Use of hsa-miR-126-3p for manufacturing an agent for preventing or treating a disease or condition associated with angiogenesis through combined use with hsa-miR-140-5p.

[Claim 4]
Use of hsa-miR-140-5p and hsa-miR-126-3p for manufacturing a VEGF production inhibitor.

[Claim 5]
Use of hsa-miR-140-5p for manufacturing an agent for inhibiting VEGF production through combined use with hsa-miR-126-3p.

[Claim 6]
Use of hsa-miR-126-3p for manufacturing an agent for inhibiting VEGF production through combined use with hsa-miR-140-5p.

[Claim 7]
The use according to any one of claims 1 to 6, wherein the disease or condition associated with angiogenesis is at least one selected from the group consisting of joint disease, shoulder stiffness, cancer,

chronic rheumatoid arthritis, cancer cell proliferation/metastasis, atherosclerosis, neovascular maculopathy, psoriasis, diabetic retinopathy, myopic choroidal neovascularization, age-related macular degeneration, enthesitis, baseball elbow, rotator cuff injury, and plantar muscle tendinitis.

[Claim 8]

The use according to claim 7, wherein the disease or condition associated with angiogenesis is joint disease.

[Claim 9]

The use according to claim 8, wherein the joint disease is knee osteoarthritis.

[Claim 10]

The use according to any one of claims 1 to 9, wherein the agent is an injectable preparation.